Affluent Medical SA (FR:AFME) has released an update.
Affluent Medical, a French MedTech company, discussed its recent operational progress in an interview on Boursorama, highlighting positive FDA feedback on its Kalios device, advancements in the Epygon valve’s clinical studies, and promising results from the Artus device’s pilot trial. The company also secured €1.1 million in non-dilutive funding for the Epygon valve’s development and received positive revisions on its share price target, indicating strong market confidence. Affluent Medical, backed by Truffle Capital, is focused on pioneering minimally invasive implants for heart diseases and urinary incontinence, aiming for commercialization by 2026.
For further insights into FR:AFME stock, check out TipRanks’ Stock Analysis page.
